Q4 2024 Achieve Life Sciences Inc Earnings Call Transcript
Key Points
- Achieve Life Sciences Inc (ACHV) plans to submit the NDA for Cytisinicline as a treatment for nicotine dependence by the end of the next quarter.
- Cytisinicline has received breakthrough therapy designation for vaping cessation, highlighting its potential impact.
- The company completed enrollment in the ORCA Open label long-term safety exposure clinical trial, meeting FDA requirements for NDA submission.
- Achieve Life Sciences Inc (ACHV) has strengthened its leadership team with new appointments, enhancing its corporate strategy and commercialization efforts.
- The company has a robust commercialization plan in place, focusing on awareness, access, and availability to ensure a successful market entry.
- Achieve Life Sciences Inc (ACHV) reported a net loss of $12.4 million for the fourth quarter and $39.8 million for the year ended December 31, 2024.
- The company's cash balance is projected to provide runway only into the third quarter of 2025, indicating potential financial constraints.
- There is uncertainty regarding the potential barriers for generics entering the market, which could impact long-term exclusivity.
- The anticipated slow ramp-up in sales post-launch due to the time required for gaining access and awareness could affect initial revenue generation.
- The company is dependent on securing additional financing to initiate the Phase 3 ORCA-V2 clinical trials for vaping cessation.
Greetings and welcome to the Achieve Life Sciences fourth-quarter and year-end 2024 earnings call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host Nicole Jones, Achieve Investor Relations. Thank you. You may begin.
Thank you, operator. Good morning, everyone, and thank you for joining us today. From Achieve Life Sciences, we are joined by Richard Stewart, Chief Executive Officer; Dr. Cindy Jacobs, President and Chief Medical Officer; Mark Oki, Chief Financial Officer; Jamie Zenos, Chief Commercial Officer, and Jerry Wan, Vice President of Finance and Principal Accounting Officer.
Management will be available for a Q&A session following our prepared remarks. As a reminder, a replay will be available later today by using the information provided in the earnings press release issued prior to this call or visiting the Achieve website.
Today's conference call will contain certain
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
